Basilea provides clinical program updates

ID: 1406378
recent pressrelease next pressrelease

(Thomson Reuters ONE) -
Basilea Pharmaceutica AG /
Basilea provides clinical program updates
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.

This press release or the information contained therein is not being issued and
may not be distributed in the United States of America, Canada, Australia or
Japan and does not constitute an offer of securities for sale in such countries

* Ceftobiprole U.S. clinical phase 3 program discussed with FDA
* Interim data from phase 1/2a study with tumor checkpoint controller
BAL101553 show signals of clinical benefit
Basel, Switzerland, December 28, 2015 - Basilea Pharmaceutica Ltd. (SIX: BSLN)
today provided an update on the planned clinical phase 3 development program for
its antibiotic ceftobiprole in the United States and reported completion of
patient recruitment and interim data from the ongoing phase 1/2a study with the
intravenous formulation of its oncology drug candidate BAL101553.

Ceftobiprole U.S. development program

Ceftobiprole (ceftobiprole medocaril) is a broad-spectrum antibiotic for
intravenous administration with bactericidal activity against Gram-positive and
Gram-negative bacteria associated with pneumonia, including methicillin-
resistant Staphylococcus aureus (MRSA) and susceptible Pseudomonas spp.[1]

Following recent discussions with the FDA, Basilea will consider conducting
cross-supportive clinical studies for the indications of acute bacterial skin
and skin structure infections, community-acquired bacterial pneumonia and
Staphylococcus aureus bloodstream infections, or bacteremia, including
endocarditis, a complication of bacteremia involving the heart valves. Basilea
currently expects that it would not initiate phase 3 studies until such time as
it has entered into a collaboration agreement with a third party.



Basilea is now preparing phase 3 study protocols for submission to the FDA in
the first quarter of 2016, seeking Special Protocol Assessments (SPAs). An SPA
provides written guidance by the FDA and documents agreement between the study
sponsor and the agency that a clinical study is adequately designed so that it
would support a regulatory submission for drug approval, should the study meet
its objectives.

Prof. Achim Kaufhold, Basilea''s Chief Medical Officer, stated: "Infections
caused by Staphylococcus aureus, and especially by methicillin-resistant
strains, are a serious healthcare issue. In preclinical models in endocarditis
and clinical studies conducted so far, ceftobiprole has demonstrated its
activity against relevant bacterial pathogens, including methicillin-susceptible
and resistant Staphylococcus aureus. Basilea is now taking a first step to
potentially make ceftobiprole available also to patients in the United States
and potentially expand the approved label in Europe."

Ceftobiprole has been approved for sale in 13 European countries[2] and Canada
for the treatment of adult patients with community-acquired pneumonia and
hospital-acquired pneumonia (excluding ventilator-associated pneumonia) and has
been launched in Germany, France, Italy and the United Kingdom. Ceftobiprole
received Qualified Infectious Disease Product (QIDP) designation from the U.S.
Food and Drug Administration for the potential treatment of community-acquired
bacterial pneumonia and acute bacterial skin and skin structure infections.
Ceftobiprole is not approved in the United States.

Phase 1/2a study with i.v. BAL101553: completion of patient recruitment and
interim results

BAL101553 is a novel small molecule tumor checkpoint controller (TCC) candidate,
promoting tumor cell death through activation of a checkpoint in cell
proliferation.[3],[4] Its intravenous formulation (i.v.) is currently being
explored in a phase 1/2a clinical study and its oral formulation in a phase 1
study, both with solid tumor patients who have failed standard therapy or for
whom no effective standard therapy is available.

In the phase 1 part of the i.v. study (24 patients), the Maximum Tolerated Dose
(MTD) was defined as 60 mg/m(2), when BAL101553 was administered intravenously
over 2 hours on day 1, 8 and 15 of 28-day treatment cycles.[5] The phase 1 study
was expanded into an open-label phase 2a study (40 evaluable patients) with the
primary objective to further evaluate the safety and tolerability of MTD and
sub-MTD doses of BAL101553.

Patient recruitment in this phase 1/2a study has been completed. Of the 72
patients dosed to date in the phase 1/2a study, 52 patients have undergone
evaluation for tumor response. One patient with an ampullary pancreatic cancer
achieved a partial response and was treated for more than two years with
BAL101553 and 12 patients had stable disease lasting between two and eight
months. For a 2-hour infusion the recommended phase 2 dose has been defined as
30 mg/m(2). The majority of patients with signals of clinical benefit, including
the partial response, were dosed at the recommended dose or below. Currently, 9
patients are still ongoing with BAL101553 treatment.

BAL101553 demonstrated anti-proliferative and anti-vascular effects as evidenced
by tumor biopsies and from circulating vascular cell levels obtained from
patients before and after dosing with BAL101553. Pharmacodynamic assessments
together with preclinical data support a separation of the anti-tumor cell from
the anti-vascular effect at different dose levels, enabling the design of
combination studies with other agents or radiotherapy where BAL101553 has shown
a combination potential in preclinical models.

Dose-limiting adverse effects in the phase 1 part of the study included
transient and reversible grade 2 to grade 3 gait disturbance which occurred
together with transient peripheral sensory neuropathy. In addition, cardiac
ischemia was observed in the phase 2a portion of the study at dose levels above
30 mg/m(2).

The recommended 2-hour intravenous dose has been defined based on the observed
good tolerability, without myelosuppression, and on pharmacodynamic and clinical
response.

Detailed analyses of the study results will be presented at upcoming scientific
conferences.

About Basilea

Basilea Pharmaceutica Ltd. is a biopharmaceutical company developing products
that address increasing resistance and non-response to current treatment options
in the therapeutic areas of bacterial infections, fungal infections and cancer.
The company uses the integrated research, development and commercial operations
of its subsidiary Basilea Pharmaceutica International Ltd. to discover, develop
and commercialize innovative pharmaceutical products to meet the medical needs
of patients with serious and potentially life-threatening conditions. Basilea
Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX
Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea''s
website www.basilea.com.

Important information

This press release constitutes neither an offer to sell nor a solicitation to
buy securities of the Company and it does not constitute a prospectus or a
similar communication within the meaning of article 752, 652a and/or 1156 of the
Swiss Code of Obligations or a listing prospectus within the meaning of the
listing rules of the SIX Swiss Exchange.

This communication is directed only at persons (i) who are outside the United
Kingdom or (ii) who have professional experience in matters relating to
investments and who fall within article 19(5) of the Financial Services and
Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order") or
(iii) who fall within article 49(2)(a) to (d) ("high net worth companies,
unincorporated associations etc.") of the Order (all such persons together being
referred to as "Relevant Persons"). Any investment or investment activity to
which this communication relates is available only to Relevant Persons and will
be engaged in only with Relevant Persons. Any person who is not a Relevant
Person must not act or rely on this communication or any of its contents.

This communication is not for distribution in the United States, Canada,
Australia or Japan. This communication does not constitute an offer to sell, or
the solicitation of an offer to buy, securities in any jurisdiction in which is
unlawful to do so. In particular, this communication is not an offer of
securities for sale in the United States. Securities may not be offered or sold
in the United States absent registration under the Securities Act of 1933 or an
exemption from registration. The securities referred to in this communication
have not been and will not be registered under the Securities Act and will not
be publicly offered or sold in the United States.

This communication does not constitute an "offer of securities to the public"
within the meaning of Directive 2003/71/EC of the European Union (the
"Prospectus Directive") of the securities referred to in it (the "Securities")
in any member state of the European Economic Area (the "EEA"). Any offers of the
Securities to persons in the EEA will be made pursuant to an exemption under the
Prospectus Directive, as implemented in member states of the EEA, from the
requirement to produce a prospectus for offers of the Securities.

Disclaimer

This communication expressly or implicitly contains certain forward-looking
statements concerning Basilea Pharmaceutica Ltd. and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition, performance
or achievements of Basilea Pharmaceutica Ltd. to be materially different from
any future results, performance or achievements expressed or implied by such
forward-looking statements. Basilea Pharmaceutica Ltd. is providing this
communication as of this date and does not undertake to update any forward-
looking statements contained herein as a result of new information, future
events or otherwise.

For further information, please contact:

+-----------------------------+--------------------------------+
| Media Relations | Investor Relations |
+-----------------------------+--------------------------------+
| Peer Nils Schröder, PhD | Barbara Zink, PhD, MBA |
| Head Public Relations & | Head Corporate Development |
| Corporate Communications | |
| +41 61 606 1102 | +41 61 606 1233 |
| media_relations(at)basilea.com | investor_relations(at)basilea.com |
+-----------------------------+--------------------------------+
This press release can be downloaded from www.basilea.com.

References

[1] Y. Y. Syed. Ceftobiprole medocaril: A review of its use in patients with
hospital- or community-acquired pneumonia. Drugs 2014 (74), 1523-1542

[2] Ceftobiprole (European trade name Zevtera(®) or Mabelio(®), depending on the
country) has received national licenses in 13 European countries for the
treatment of adult patients with community- and hospital-acquired pneumonia
(CAP, HAP), excluding ventilator-associated pneumonia (VAP): Austria, Belgium,
Denmark, Finland, France, Germany, Italy, Luxembourg, Norway, Spain, Sweden,
Switzerland and the United Kingdom.

[3] F. Bachmann, K. Burger, H. Lane. BAL101553 (prodrug of BAL27862): the
spindle assembly checkpoint is required for anticancer activity. American
Association for Cancer Research (AACR) annual meeting 2015, abstract 3789

[4] R. Berges et al. The novel tubulin-binding ''tumor checkpoint controller''
BAL101553 exerts EB1 expression-dependent antitumor effects on glioblastoma
stem-like cells in vitro and in vivo. AACR-NCI-EORTC International Conference on
Molecular Targets and Cancer Therapeutics, November 2015, abstract A183

[5] L. R. Molife et al. Phase 1/2a trial of the novel microtubule inhibitor
BAL101553 in advanced solid tumors: Phase 1 completed. American Society of
Clinical Oncology (ASCO) annual meeting 2014, abstract 2562


Press release (PDF):
http://hugin.info/134390/R/1975918/723124.pdf



This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Basilea Pharmaceutica AG via GlobeNewswire
[HUG#1975918]






More information:
http://www.stickitpro.net/ http://www.ratos.se http://divorced.singles.dating/ http://www.basilea.com



Keywords (optional):



Company information / Profile:

PressRelease by

Requests:



PressContact / Agency:



published by: hugin
print pressrelease  send to a friend  

Date: 12/28/2015 - 01:15
Language: English
News-ID 1406378
Character count: 2885
Kontakt-Informationen:
Firma: Basilea Pharmaceutica AG
Ansprechpartner: Feedback to businesspress24.com about Pressrelease-id:
Stadt: Basel
Telefon:

Meldungsart:
Versandart:
Freigabedatum:
Comments:



Number of hits: 275

Linking-Tips:



Direct Link to this PressRelease:






We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease






All members: 9 433
Register today: 0
Register yesterday: 1
Members online: 0
Guests online: 61


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.